BIT 0.00% 2.2¢ biotron limited

Ann: Update on Phase 2 Trial and IND Progress, page-27

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 409 Posts.
    lightbulb Created with Sketch. 4
    I think J8's response largely covers it. Harvoni is pangenotypic, not for G1 only. As mentioned before, BIT225 has NEVER been used in a cirrhotic patient nor a previous treatment failure, the most difficult groups which are now included in all advanced trials of DAA's. Unless a drug cuts the mustard there, it has no hope of future use in HCV.
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.